Clinical bottom line
Fatigue is a prevalent and debilitating symptom in patients with advanced heart failure (HF) receiving palliative care. Current evidence supports a multifaceted approach combining optimized HF medical management, tailored physical activity, psychosocial support, and symptom-targeted interventions to alleviate fatigue and improve quality of life. Early integration of palliative care principles into HF management facilitates comprehensive symptom assessment and individualized care planning. However, evidence specifically addressing fatigue management in this population remains limited, warranting cautious interpretation and further research.
What the evidence shows
Fatigue in advanced HF is multifactorial, arising from cardiac dysfunction, comorbidities, medication side effects, and psychosocial factors (Lowey et al., 2018). It significantly impairs functional status and quality of life, often persisting despite standard HF therapies (Gadoud et al., 2024). Palliative care integration enables systematic symptom assessment and holistic management, which has been shown to improve patient-reported outcomes in nononcological populations including HF (Mós et al., 2025).
Pharmacological optimization of HF, including guideline-directed medical therapy (GDMT), remains foundational to fatigue management by improving cardiac output and reducing congestion (Kida et al., 2020). Diuretics, ACE inhibitors, beta-blockers, and mineralocorticoid receptor antagonists may indirectly reduce fatigue by stabilizing HF symptoms (Antonione et al., 2020). However, medication side effects such as hypotension or anemia can exacerbate fatigue and require careful balancing (Anwar et al., 2012).
Nonpharmacological interventions, particularly individualized physical activity and rehabilitation programs, have demonstrated benefits in reducing fatigue and enhancing functional capacity in advanced HF (Lowey et al., 2018). Even low-intensity exercise tailored to patient tolerance can mitigate deconditioning and improve energy levels. Psychosocial support addressing depression, anxiety, and social isolation is also critical, as these factors contribute substantially to fatigue severity (Gadoud et al., 2024).
Symptom-targeted therapies, including management of anemia, sleep disturbances, and nutritional deficits, may further alleviate fatigue (Kida et al., 2020). Evidence for pharmacologic fatigue-specific agents (e.g., psychostimulants) in HF is sparse and inconclusive, underscoring the need for individualized risk-benefit assessment.
Early palliative care involvement facilitates advance care planning and shared decision-making, aligning fatigue management with patient goals and preferences (Mós et al., 2025). This approach supports holistic care beyond symptom control, addressing existential distress and caregiver burden.
Caveats and uncertainty
The evidence base for fatigue management in advanced HF within palliative care is limited by small, heterogeneous studies and a paucity of randomized controlled trials focused specifically on fatigue as a primary outcome (Mosoiu et al., 2020). Most data derive from broader symptom management or rehabilitation studies, limiting direct applicability.
Pharmacological interventions targeting fatigue lack robust evidence in this population, and potential adverse effects necessitate caution. The optimal intensity and modality of physical activity remain to be clearly defined, particularly in severely debilitated patients.
Psychosocial interventions are variably implemented and studied, with limited standardized protocols. Cultural, socioeconomic, and health system factors may influence access and effectiveness of palliative care services, affecting fatigue outcomes.
Finally, fatigue is inherently subjective and multifactorial, complicating assessment and response evaluation. Standardized, validated fatigue measurement tools specific to HF palliative care are needed.
How this may change practice
Clinicians caring for patients with advanced HF should prioritize early palliative care integration to enable comprehensive fatigue assessment and multidisciplinary management. Optimizing HF medical therapy remains essential but should be balanced against potential fatigue-exacerbating side effects.
Incorporating tailored physical activity programs, even at low intensity, may improve fatigue and functional status and should be considered part of routine care. Addressing psychosocial contributors through counseling, support groups, or psychiatric referral may enhance fatigue management.
Symptom-targeted interventions such as anemia correction and sleep optimization warrant evaluation and treatment when appropriate. Clinicians should engage patients and families in shared decision-making to align fatigue management strategies with individual goals and quality of life priorities.
Ongoing research is needed to establish evidence-based fatigue-specific therapies and standardized assessment tools in this population. Meanwhile, a personalized, holistic approach grounded in palliative care principles offers the best current strategy.